WilmerHale Advises Thermo Fisher Scientific in €1.6B Eurobond Public Offering

WilmerHale Advises Thermo Fisher Scientific in €1.6B Eurobond Public Offering

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
A premier corporate governance and disclosure practice providing timely, tailored and practical advice to public company clients based on in-depth experience and insight.
WilmerHale’s corporate lawyers have a long history of experience with cross-border deals involving mergers and acquisitions, public offerings and capital markets, venture capital, joint ventures and other transactions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Thermo Fisher Scientific Inc., a provider of equipment, software and services for research, manufacturing, analysis, discovery and diagnostics, announced the completion of its public offering of  €1 billion aggregate principal amount of 0.750% Senior Notes due 2024 and €600 million aggregate principal amount of 1.375% Senior Notes due 2028 at the issue prices of 99.122% of the principal amount and 99.748% of the principal amount, respectively. The offering closed on September 12, 2016.

The WilmerHale team was led by Partner Knute Salhus and included Partners John Sigel, Julie Hogan Rodgers, Tim Silva, Senior Associate Ryan Mitteness, and Associates Tim Hultzman and Seth Davis.

For more information, read Thermo Fisher Scientific's press release.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel